Technical Analysis for ALXN - Alexion Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 116.0 -1.09% -1.28
ALXN closed down 1.09 percent on Friday, August 17, 2018, on 79 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ALXN trend table...

Date Alert Name Type % Chg
Aug 17 Inside Day Range Contraction 0.00%
Aug 17 Oversold Stochastic Weakness 0.00%
Aug 16 Oversold Stochastic Weakness -1.09%
Aug 15 Downside 200 DMA Break Bearish 0.59%
Aug 15 Oversold Stochastic Weakness 0.59%
Aug 14 Upside 200 DMA Break Bullish -3.07%
Aug 14 Multiple of Ten Bearish Other -3.07%
Aug 14 Oversold Stochastic Weakness -3.07%
Aug 13 200 DMA Resistance Bearish -2.00%
Aug 13 NR7 Range Contraction -2.00%

Older signals for ALXN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Is ALXN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 149.34
52 Week Low 102.1
Average Volume 1,412,969
200-Day Moving Average 118.9153
50-Day Moving Average 126.2576
20-Day Moving Average 125.7155
10-Day Moving Average 119.177
Average True Range 3.1552
ADX 36.49
+DI 9.6825
-DI 30.3699
Chandelier Exit (Long, 3 ATRs ) 129.3044
Chandelier Exit (Short, 3 ATRs ) 123.8656
Upper Bollinger Band 140.4551
Lower Bollinger Band 110.9759
Percent B (%b) 0.17
BandWidth 23.449137
MACD Line -3.5147
MACD Signal Line -2.1989
MACD Histogram -1.3159
Fundamentals Value
Market Cap 25.89 Billion
Num Shares 223 Million
EPS 2.31
Price-to-Earnings (P/E) Ratio 50.22
Price-to-Sales 8.25
Price-to-Book 3.18
PEG Ratio 1.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 118.75
Resistance 3 (R3) 118.87 118.07 118.29
Resistance 2 (R2) 118.07 117.37 118.01 118.13
Resistance 1 (R1) 117.04 116.94 116.64 116.92 117.98
Pivot Point 116.24 116.24 116.05 116.18 116.24
Support 1 (S1) 115.21 115.54 114.81 115.09 114.02
Support 2 (S2) 114.41 115.11 114.35 113.87
Support 3 (S3) 113.38 114.41 113.71
Support 4 (S4) 113.26